GPRC5D and Miyoshi myopathy: Additionally, a phase 1 trial (NCT04108195) of subcutaneous daratumumab in combination with intravenous JNJ-64007957 or JNJ-64407564 (i.e., an anti-GPRC5D BsAb) in patients with MM started in January 2020.